Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials.

@article{RomnGonzlez2017MalignantPP,
  title={Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials.},
  author={Alejandro Rom{\'a}n-Gonz{\'a}lez and Camilo Jim{\'e}nez},
  journal={Current opinion in endocrinology, diabetes, and obesity},
  year={2017},
  volume={24 3},
  pages={174-183}
}
PURPOSE OF REVIEW Pheochromocytomas and paragangliomas (PPGs) are rare neuroendocrine tumors. Over the last 15 years, substantial progress has been made toward understanding the clinical aspects and molecular origins of this disease. Nevertheless, predicting and managing malignancy remains the biggest challenge in clinical practice. The natural history of patients with malignant PPGs has not yet been described, and their prognosis varies. Currently, the diagnosis of malignant PPGs relies on the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS
11 Citations
75 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 75 references

Antitumor activity of the ATR inhibitor AZD 6738 in HER 2 positive breast cancer cells

  • HJ Kim, A Min, SA Im
  • Int J Cancer
  • 2017

Similar Papers

Loading similar papers…